Mode
Text Size
Log in / Sign up

Network meta-analysis finds medium-dose vitamin A superior to high-dose for pediatric pneumonia.

Network meta-analysis finds medium-dose vitamin A superior to high-dose for pediatric pneumonia.
Photo by Logan Voss / Unsplash
Key Takeaway
Consider low-to-medium dose vitamin A over high-dose for pediatric pneumonia symptoms, noting evidence limitations.

This is a network meta-analysis of randomized controlled trials evaluating different doses of vitamin A supplementation for children with pneumonia. The analysis synthesized evidence from a total sample of 3116 children, comparing low, medium, and high-dose regimens.

The authors found that medium-dose vitamin A supplementation was most effective for reducing the duration of fever and the duration of cough. For overall clinical outcomes, low-to-medium doses were consistently associated with better results than high-dose regimens. No pooled effect sizes, absolute numbers, or p-values were reported for these findings.

Key limitations noted by the authors include high heterogeneity among the included trials, the use of indirect comparisons between dose groups, and poor reporting of adverse events. Safety evidence was limited and inconclusive, with no serious adverse events reported.

The practice relevance is that low-to-medium dose vitamin A supplementation appears superior to high-dose regimens for alleviating clinical symptoms in children with pneumonia. However, the certainty of this evidence is limited, and the findings should not be interpreted as direct causal evidence due to the network meta-analysis design.

Study Details

Study typeMeta analysis
Sample sizen = 3,116
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
UNLABELLED: While previous meta-analyses have established a link between vitamin A supplementation and outcomes in children with pneumonia, the efficacy and safety of different dosing regimens remain unclear. Existing evidence is predominantly based on single-dose trials, creating a critical knowledge gap. We systematically searched PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang and VIP databases from their inception to December 2025. Study searches were independently carried out in December 2025 by two reviewers. Two researchers used the Cochrane risk of bias tool to independently assess the quality of the included studies. Data analysis was conducted through the "netmeta" package in R software (version 4.3.3). Twenty-five trials involving 3116 patients were included. Network meta-analysis revealed that medium-dose vitamin A supplementation was most effective in reducing the duration of fever and cough. Low-to-medium doses were consistently associated with better clinical outcomes than high-dose regimens. However, evidence regarding safety outcomes remained limited and inconclusive. CONCLUSION:  Low-to-medium dose vitamin A supplementation appears superior to high-dose regimens for alleviating clinical symptoms in children with pneumonia. However, the evidence is limited by high heterogeneity, indirect comparisons between dose groups, and poor reporting of adverse events. Future trials should prioritize direct dose-comparisons and rigorous safety monitoring to refine dosing guidelines. WHAT IS KNOWN: • Pneumonia poses a significant threat to the health and lives of children. Vitamin A supplementation plays an adjuvant role in the treatment of pneumonia in children. • There are currently divergent conclusions in the research regarding the optimal dosage of vitamin A, particularly with regard to the safety of high-dose supplementation and the effectiveness of low-dose supplementation. WHAT IS NEW: • This study revealed that medium-to-low-dose vitamin A supplementation appears to be more effective than high-dose therapy in alleviating the primary symptoms of childhood pneumonia. • This study also suggests that children in developed regions have higher baseline serum retinol levels, which may diminish the marginal benefits of high-dose supplementation and may even predispose them to its immunosuppressive effects.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.